Upcoming Technologies to Facilitate More Efficient Biologics Manufacturing - Choosing the right tools to enhance the process. - BioPharm International

ADVERTISEMENT

Upcoming Technologies to Facilitate More Efficient Biologics Manufacturing
Choosing the right tools to enhance the process.


BioPharm International
Volume 22, Issue 2


Figure 4
Experiments were conducted with a recombinant E. coli solution at a cell density of approximately 4% w/w for production of a plasmid used for gene therapy treatment. The primary objective of the application was to concentrate the E. coli feed by a minimum concentration factor of 10-fold using a single-use technology. Initial trials were conducted with the small-scale device and the filtrate flux rate for concentration was selected to be 22.5 LMH. It was estimated that six full-scale modules (membrane area of 3 m2) will be required to process 500 L of feed at a feed flow rate of approximately 21 L/min (CFF of 7 L/min/m2). To demonstrate scalability to a series and parallel configuration, a trial was conducted to compare the performance of a single full-scale module against the performance of three full-scale modules operated in series. The filtrate flux rate was maintained at 22.5 LMH for each module throughout the trial. Pressure gauges were installed throughout the system to enable accurate TMP determination across each module. The results shown in Figure 4 indicate that each of the three capsules manifolded together in series provided a VT versus TMP curve very similar to a single module operated in isolation.

In summary, the Kleenpak TFF MF capsules' single-use TFF technology offers major benefits for cell harvesting and clarification. The self-contained format eliminates the need to purchase and install holders or housings and also reduces exposure to biologically active solutions. This is a critical consideration for manufacturers of vaccines and other products that present potential workplace hazards. The optimized feed channel screen provides good performance at low flows and the technology is scalable and reproducible.

HYDROPHOBIC INTERACTION MEMBRANE CHROMATOGRAPHY


Table 1
Sartobind Phenyl membrane adsorber from Sartorius Stedim Biotech (Goettingen, Germany) uses hydrophobic interaction chromatography (HIC) principles and assembled into a 30-layer radial flow process capsule (Sartobind). It is based on hydrophilic regenerated stabilized cellulose with the hydrophobic phenyl groups covalently attached to the cellulose matrix. The novel macroporous membrane structure with 1–3 m pores has been designed for high flow rates and high binding capacities. As seen in Table 1, the binding capacity for a MAb on HIC membrane is found to be at par with conventional HIC resins even at significantly higher flow rates. Two MAbs were loaded onto a membrane device and on a column at specified flow rates. The bed height for the column was 30 mm and 8 mm for the membrane. The dynamic binding capacity as illustrated in Figure 5A was similar for the two formats. Combining the advantages of membrane chromatography with virtually no diffusion limitation, shorter processing time because of convective flow, and a ready-to-use disposable capsule format, the Sartobind HIC membrane adsorber represents a new membrane-based tool applicable for flow-through as well as bind-and-elute applications. It provides a robust alternative capturing large and unstable molecules that need to be processed rapidly.


Figure 5
At least two subsequent polishing steps are typically implemented in MAb downstream processes. The Sartobind anion exchange membrane chromatography in combination with a hydrophobic interaction membrane chromatography offers different selectivities and could reduce host cell proteins, high molecular weight aggregates, DNA, and leached protein A to acceptably low levels that assure safety of the product. This may enable the downstream process to be just a one-column-step purification process.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
Author Guidelines
Source: BioPharm International,
Click here